CathRx looks to delist from ASX
10 May, 2012 by Dylan Bushell-EmblingCardiac catheter company CathRx (ASX:CXD) will likely seek shareholder approval to go private after it raises funds to pursue a potential sale of the company.
BioDiem, VIVALIS team for viral vector research
09 May, 2012 by Dylan Bushell-EmblingBioDiem (ASX:BDM) and France's VIVALIS are exploring the feasibility of using BioDiem's LAIV flu virus to create a viral vector for non-influenza vaccines.
Science and biotech survive surplus budget
09 May, 2012 by Tim DeanDespite a budget riddled with cuts, funding for science has increased and the recently-passed R&D Tax Incentive has remained intact.
Flu license fees nothing to sneeze at for BioDiem
08 May, 2012 by Dylan Bushell-EmblingBioDiem (ASX:BDM) has received license fees totalling around 10% of its market cap from its LAIV flu vaccine technology.
Hydrix wins Victorian enabling technology award
08 May, 2012 by Dylan Bushell-EmblingHydrix, an engineering consultancy company operating in the medical device and other sectors, has won an award from the Victorian Manufacturing Hall of Fame.
Registrations now open for the biotechnology event of the year, AusBiotech 2012
08 May, 2012 by AusBiotechReturning to Melbourne this year, the biotechnology industry event of the year, AusBiotech 2012 national conference, is now open for registration.
Immuron taps NZ dairy for colostrum production
07 May, 2012 by Dylan Bushell-EmblingImmuron (ASX:IMC) has signed a deal with dairy processing company Synlait covering the production of colostrum needed for its Travelan drug.
IQnovate to commercialise Nanosonics’ disinfection system
03 May, 2012 by Dylan Bushell-EmblingContract medical company IQnovate (ASX:IQN) has signed an MoU with Sydney's Nanosonics to help commercialise an ultrasound disinfection system.
Industry update from AusBiotech and PwC
03 May, 2012 by AusBiotechAusBiotech’s CEO, Dr Anna Lavelle and PricewaterhouseCoopers’ (PwC) Partner, Craig Lawn, sat down to discuss the state of the biotechnology and life sciences sector on webcast, including the impact of the R&D Tax Credit, changes in the market for capital as well as current and emerging trends.
AtCor launches improved blood pressure test
02 May, 2012 by Dylan Bushell-EmblingAtCor Medical (ASX:ACG) has launched SphygmoCor XCEL, the newest iteration of its non-invasive central aortic blood pressure monitoring device.
Osprey Medical completes $20m IPO
02 May, 2012 by Dave KearnsShares in Osprey Medical (ASX:OSP), a US medical device company commercialising a product which uses Australian IP, began trading on the ASX on Wednesday.
Handheld plasma torch is like a lightsaber against bacteria
01 May, 2012 by Tim DeanA battery-powered handheld plasma torch developed by Australian and Chinese scientists has been shown to wipe out some of the nastiest bacteria on skin surfaces.
Set price fees for R&D Tax Incentive claims and advance findings
01 May, 2012 by AusBiotechThree tax-specialist accounting firms are offering AusBiotech members free consultations and set prices for R&D Tax Incentive claims and advance findings.
Ventus Medical launches $40m IPO
30 April, 2012 by Dylan Bushell-EmblingVentus Medical, a US-based company that develops products for sleep-disordered breathing, has launched a $40 million IPO on the ASX.
ResMed posts record $65m profit as US market strengthens
30 April, 2012 by Dylan Bushell-EmblingResMed (ASX:RMD) has revealed its March quarter profit grew 21% to $65 million, on the back of strong demand for its respiratory products in the Americas.
